July 2026 in “Journal of the American Academy of Dermatology” Finasteride may lower depression risk in younger men with hair loss but increase it in older men with prostate issues.
1 citations
,
August 2017 in “The Journal of urology/The journal of urology” 5α-reductase inhibitors may increase the risk of depression and suicidal thoughts.
February 2026 in “Postgraduate Medicine” 5-alpha reductase inhibitors slightly increase depression risk, but the risk varies based on the control group used.
17 citations
,
September 2013 in “The International Journal of Neuropsychopharmacology”
75 citations
,
January 2014 in “Korean Journal of Urology” 5α-reductase inhibitors can cause sexual problems, higher risk of aggressive prostate cancer, and depression.
9 citations
,
December 2023 in “Journal of Neuroimmune Pharmacology” NDP-MSH protects brain cells and reduces inflammation in Parkinson's disease by activating MC1R and involving Tregs.
December 2025 in “The Journal of Clinical Psychiatry” Finasteride can cause depression and suicidal thoughts; safer alternatives are recommended.
December 2021 in “OPAL (Open@LaTrobe) (La Trobe University)” Montelukast is linked to increased risks of suicidal thoughts and depression.
February 2023 in “Reactions Weekly” Androgens increase norepinephrine release, promoting smooth muscle growth in male sex organs, which may contribute to benign prostatic hypertrophy.
2 citations
,
June 2018 in “Physiology & behavior” Early changes in brain chemicals affect how a drug reduces alcohol intake in rats.
August 2017 in “Drug and Therapeutics Bulletin” Finasteride may cause depression, suicidal thoughts, and sexual side effects.
56 citations
,
February 2006 in “American journal of physiology. Cell physiology” Steroid sex hormones activate matriptase in prostate cancer cells but not in breast cancer cells.
19 citations
,
January 2011 in “Frontiers in Endocrinology” Social isolation makes mice more sensitive to alcohol's effects on brain function.
20 citations
,
November 2019 in “Biomolecules” Finasteride reduces response to stress and rewards, affecting behavior and mental health.
December 2023 in “Alzheimer's & Dementia” Long-term use of a drug for hair loss and prostate issues can cause metabolic problems and depression-like behavior in young male rats.
August 2022 in “Theriogenology” Neurosteroids affect prolactin levels in sheep differently depending on stress and pregnancy conditions.
8 citations
,
September 1993 in “Human psychopharmacology” Some antidepressants can cause rare hair loss, which can significantly affect patients' well-being.
March 2026 in “Preprints.org” Plerixafor may help treat pigmentation disorders by promoting skin repigmentation.
151 citations
,
December 2004 in “Neuropharmacology” Progesterone reduces anxiety without needing progesterone receptors.
April 2023 in “Journal of Investigative Dermatology” Acne patients have higher skin mTORC1 activity, which is reduced by isotretinoin treatment.
June 2025 in “Pharmaceuticals” Finasteride use may increase suicidality risk, especially in young men.
2 citations
,
September 2009 in “Hormone Molecular Biology and Clinical Investigation” Low dose finasteride decreases certain steroids, possibly increasing depression risk.
9 citations
,
February 2022 in “Biomedicines” Testosterone treatment may change estrogen receptor methylation in AFAB individuals.
64 citations
,
March 2008 in “Neuropsychopharmacology”
1 citations
,
December 2022 in “Archives of Dermatological Research” Acne treatment with isotretinoin increases the presence of p53, a protein, in skin and oil glands, which may help reduce acne severity.
December 2025 in “BJPsych Open” Semaglutide may worsen eating disorders in vulnerable individuals.
11 citations
,
January 2020 in “Epidemiology and Psychiatric Sciences” Antidepressants can cause long-term side effects like severe withdrawal symptoms and sexual dysfunction, which can last for months or years after stopping the medication.
91 citations
,
May 2003 in “PubMed” Neuroactive steroids affect cocaine's rewarding effects through the sigma1 receptor.
February 2025 in “International Urology and Nephrology” Peripheral treatments showed some improvement in sexual dysfunction, but central symptoms remain challenging.